Soleus Capital Administration disclosed a major purchase of Vericel (NASDAQ:VCEL), including 1,785,079 shares within the first quarter—an estimated $63.40 million commerce primarily based on quarterly common pricing—in keeping with a Could 14, 2026, SEC submitting.
What occurred
Based on a SEC submitting dated Could 14, 2026, Soleus Capital Administration, L.P. elevated its place in Vericel by 1,785,079 shares throughout the first quarter. The estimated transaction worth was $63.40 million, calculated utilizing the interval’s common closing worth. The quarter-end worth of the stake elevated by $54.49 million, a determine reflecting each new purchases and underlying worth modifications.
What else to know
-
The submitting displays a purchase; Vericel now represents 3.32% of Soleus Capital’s 13F property beneath administration.
-
Prime 5 holdings following the submitting:
-
NASDAQ:KRYS: $297.87 million (12.1% of AUM)
-
NASDAQ:CELC: $146.60 million (5.9% of AUM)
-
NASDAQ:TGTX: $133.85 million (5.4% of AUM)
-
NASDAQ:PODD: $118.03 million (4.8% of AUM)
-
NASDAQ:NVCR: $114.37 million (4.6% of AUM)
-
-
As of Friday, Vericel shares have been priced at $33.33, down about 20% over the previous 12 months and nicely underperforming the S&P 500, which is up 28%.
Firm overview
|
Metric |
Worth |
|---|---|
|
Worth (as of Friday) |
$33.33 |
|
Market Capitalization |
$1.7 billion |
|
Income (TTM) |
$292.1 million |
|
Web Earnings (TTM) |
$21.5 million |
Firm snapshot
-
Vericel develops and markets autologous cell remedy merchandise, together with MACI for cartilage restore and Epicel for extreme burn remedy; it additionally has NexoBrid within the preapproval stage for burn care.
-
The corporate generates income by manufacturing and distributing proprietary mobile therapies, primarily concentrating on sports activities drugs and burn care markets in the USA.
-
Its essential clients are hospitals, clinics, and specialised medical facilities treating orthopedic accidents and extreme burns in grownup and pediatric sufferers.
Vericel is a commercial-stage biopharmaceutical firm specializing in superior cell therapies for orthopedic and burn care indications.
What this transaction means for traders
Whereas Vericel’s inventory has struggled over the previous 12 months, the underlying enterprise continues to publish the sort of progress and margin enlargement that long-term healthcare traders are inclined to search for.
The corporate’s newest outcomes confirmed why. Second-quarter income climbed 20% 12 months over 12 months to $63.2 million, pushed by 21% progress from its flagship MACI cartilage restore remedy. Gross margin expanded to 74%, up greater than 4 proportion factors from a 12 months earlier, whereas adjusted EBITDA greater than doubled to $13.4 million. The corporate additionally ended the quarter with roughly $164 million in money and investments and no debt.
Administration seems more and more assured within the runway forward. CEO Nick Colangelo highlighted continued momentum from the MACI Arthro launch and mentioned the corporate expects “continued sturdy income progress and profitability” by the rest of the 12 months. Vericel additionally obtained FDA clearance to start a Part 3 examine evaluating MACI for ankle cartilage defects, opening one other potential progress avenue.
In different phrases, it appears Vericel is turning into a commercial-stage enterprise with rising income, increasing margins, and a number of alternatives to deepen adoption of current merchandise. That mixture possible explains why a specialist healthcare fund was prepared so as to add aggressively regardless of latest inventory weak spot.
